Product Information
ATOVAQUONE-PROGUANIL 62.5-25 is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $1.0400 per EA under NDC 00378416001. Its NADAC has been published 478 times since Aug 6, 2014.
FDA first approved this application on May 27, 2014. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The Low Outlier badge above means this manufacturer's average price in the atovaquone and proguanil hydrochloride market falls below Q1 − 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
62.5; 25 mg/1; mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378416001
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
ATOVAQUONE; PROGUANIL HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA202362FDA Approved
5/27/2014
TE Code
AB
On Market Since
5/28/2014
Pharmacological Classes
Price Statistics
The NADAC for ATOVAQUONE-PROGUANIL 62.5-25 has been published 478 times since Aug 6, 2014, and over the history we have for it it has declined 44.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.0400 per EA |
|---|---|
| All-time high | $1.9634 (Mar 11, 2015) |
| All-time low | $0.6264 (Sep 21, 2022) |
| 52-week high | $1.3157 |
| 52-week low | $1.0400 |
| Median price | $1.3863 |
| Average price | $1.3912 |
| Largest weekly change | -62.2% (Sep 21, 2022) |
| Weeks tracked | 478 |
| Tracking since | Aug 6, 2014 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the atovaquone and proguanil hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of ATOVAQUONE-PROGUANIL 62.5-25?
The current National Average Drug Acquisition Cost (NADAC) for ATOVAQUONE-PROGUANIL 62.5-25, manufactured by Mylan Pharmaceuticals Inc., is $1.0400 per EA (NDC 00378416001), effective Aug 19, 2026.
How has the price of ATOVAQUONE-PROGUANIL 62.5-25 changed over time?
Over the history we have for it, the NADAC for ATOVAQUONE-PROGUANIL 62.5-25 has declined 44.8%. It has been tracked across 478 weekly CMS publications since Aug 6, 2014.
What are the highest and lowest recorded NADAC prices for ATOVAQUONE-PROGUANIL 62.5-25?
Since Aug 6, 2014, the NADAC for ATOVAQUONE-PROGUANIL 62.5-25 has ranged from a low of $0.6264 (Sep 21, 2022) to a high of $1.9634 (Mar 11, 2015), with a median of $1.3863 per EA.
Are there cheaper alternatives to ATOVAQUONE-PROGUANIL 62.5-25?
No other NADAC-published product currently shares the active ingredient and strength of ATOVAQUONE-PROGUANIL 62.5-25 in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ATOVAQUONE-PROGUANIL 62.5-25?
ATOVAQUONE-PROGUANIL 62.5-25 (NDC 00378416001) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.